Cyteir Therapeutics, Inc.
CYTNASDAQHealthcare
$3.02
$-0.07(-2.27%)
Market Cap$108714262
P/E Ratio—
52W High$3.19
52W Low$1.65
Cyteir Therapeutics, Inc. (CYT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CYT · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Mar 28, 2024EPS Actual
-$0.25
Est. -$0.20 · -25.0%
Revenue
—
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Mar 28, 2024
After Market Close
▼ Miss EPS
CYT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Mar 28, 2024 | -$0.20 | -$0.25 | -25.0% | — | — | — |
| — Q4 FY2023 | Nov 6, 2023 | — | -$0.10 | — | — | — | — |
| ▲ Q3 FY2023 | Aug 7, 2023 | -$0.32 | -$0.24 | +25.0% | — | — | — |
| ▼ Q2 FY2023 | May 10, 2023 | -$0.27 | -$0.35 | -29.6% | — | — | — |
| ▲ Q1 FY2023 | Mar 23, 2023 | -$0.34 | -$0.25 | +26.5% | — | — | — |
| ▲ Q4 FY2022 | Nov 7, 2022 | -$0.41 | -$0.31 | +24.4% | — | — | — |
| ▲ Q3 FY2022 | Aug 8, 2022 | -$0.44 | -$0.34 | +22.7% | — | — | — |
| ▼ Q2 FY2022 | May 5, 2022 | -$0.39 | -$0.40 | -2.6% | — | — | — |
Q1 FY2024
Mar 28, 2024Miss
EPS Actual
-$0.25
EPS Est.
-$0.20
EPS Surpr.
-25.0%
Revenue
—
Q4 FY2023
Nov 6, 2023
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 7, 2023Beat
EPS Actual
-$0.24
EPS Est.
-$0.32
EPS Surpr.
+25.0%
Revenue
—
Q2 FY2023
May 10, 2023Miss
EPS Actual
-$0.35
EPS Est.
-$0.27
EPS Surpr.
-29.6%
Revenue
—
Q1 FY2023
Mar 23, 2023Beat
EPS Actual
-$0.25
EPS Est.
-$0.34
EPS Surpr.
+26.5%
Revenue
—
Q4 FY2022
Nov 7, 2022Beat
EPS Actual
-$0.31
EPS Est.
-$0.41
EPS Surpr.
+24.4%
Revenue
—
Q3 FY2022
Aug 8, 2022Beat
EPS Actual
-$0.34
EPS Est.
-$0.44
EPS Surpr.
+22.7%
Revenue
—
Q2 FY2022
May 5, 2022Miss
EPS Actual
-$0.40
EPS Est.
-$0.39
EPS Surpr.
-2.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Mar 28, 2024 | -25.0% | $3.01 | $3.01 | +0.00% |
| — Q4 FY2023 | Nov 6, 2023 | — | $3.00 | $3.00 | +0.00% |
| ▲ Q3 FY2023 | Aug 7, 2023 | +25.0% | $2.75 | $2.72 | -1.09% |
| ▼ Q2 FY2023 | May 10, 2023 | -29.6% | $2.16 | $2.17 | +0.46% |
| ▲ Q1 FY2023 | Mar 23, 2023 | +26.5% | $1.72 | $1.79 | +4.07% |
| ▲ Q4 FY2022 | Nov 7, 2022 | +24.4% | $1.70 | $1.75 | +2.94% |
| ▲ Q3 FY2022 | Aug 8, 2022 | +22.7% | $2.49 | $2.58 | +3.61% |
| ▼ Q2 FY2022 | May 5, 2022 | -2.6% | $2.47 | $2.03 | -18.02% |
Q1 FY2024+0.00%
Report Date
Mar 28, 2024
EPS Beat/Miss
-25.0%
Price Before
$3.01
Price After
$3.01
Q4 FY2023+0.00%
Report Date
Nov 6, 2023
EPS Beat/Miss
—
Price Before
$3.00
Price After
$3.00
Q3 FY2023-1.09%
Report Date
Aug 7, 2023
EPS Beat/Miss
+25.0%
Price Before
$2.75
Price After
$2.72
Q2 FY2023+0.46%
Report Date
May 10, 2023
EPS Beat/Miss
-29.6%
Price Before
$2.16
Price After
$2.17
Q1 FY2023+4.07%
Report Date
Mar 23, 2023
EPS Beat/Miss
+26.5%
Price Before
$1.72
Price After
$1.79
Q4 FY2022+2.94%
Report Date
Nov 7, 2022
EPS Beat/Miss
+24.4%
Price Before
$1.70
Price After
$1.75
Q3 FY2022+3.61%
Report Date
Aug 8, 2022
EPS Beat/Miss
+22.7%
Price Before
$2.49
Price After
$2.58
Q2 FY2022-18.02%
Report Date
May 5, 2022
EPS Beat/Miss
-2.6%
Price Before
$2.47
Price After
$2.03
Avg Beat Reaction+2.38%
Avg Miss Reaction-5.85%
Beat Rate4 / 8 quarters
Largest Move-18.02% (Q2 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CYT ends December
Cyteir Therapeutics, Inc. (CYT) most recently reported earnings on March 28, 2024 for Q1 FY2024, posting EPS of $-0.25 — missing the analyst consensus of $-0.20 by -25.0%. The next CYT earnings date is expected around September 1, 2026.
Each quarter, investors track CYT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CYT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CYT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CYT earnings · 5 questionsCyteir Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CYT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CYT historically reports after market close (AMC).
CYT earnings datewhen is CYT earningsCYT next earnings datewhen does CYT report earningsCYT earnings calendar
▸ Source: FMP · Cyteir Therapeutics, Inc. SEC filings · US GAAP · Cyteir Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026